Anti-NMDA receptor encephalitis in a toddler: A diagnostic challenge

Yasmin Khundakji, Amira Masri, Najwa Khuri-Bulos

1. Introduction

Anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis is a synaptic autoimmune disorder that was first characterized in 2007 [1]. Since then, the definition evolved to include a wide spectrum of ages and presentations, and it is now considered to be one of the most common causes of encephalitis in children [2]. In children, the most commonly reported clinical manifestations include abnormal behavior, movement disorders, and seizures [2]. Although around 40% of all reported cases with anti-NMDA receptor encephalitis are children [2], however, the number of studies that report infants and toddlers is very small. Furthermore, reports on children from the Middle East particularly are extremely rare.

We report a 21-month-old Jordanian female toddler with NMDAR encephalitis, who initially presented with behavioral changes and some autistic features. She presented a diagnostic challenge due to a concurrent urinary tract infection and gastroenteritis. Multiple investigations were conducted and she was treated with methylprednisolone and intravenous immunoglobulin (IVIg) empirically as well as plasma exchange and rituximab once the diagnosis was confirmed. Her condition improved gradually. We discuss her clinical picture and the diagnostic challenges within this age group; we also review the current related literature.

2. Case report

The patient was a healthy girl. At 21 months, she developed sudden behavioral changes manifesting as bouts of irritability, aggression, inconsolable crying, and self-mutilatory behavior (self-biting). She developed a fever a few days later which was attributed to a urinary tract infection and was followed by vomiting and diarrhea resulting from Rota virus gastroenteritis.

Her condition worsened over the course of two weeks and the fever persisted. She no longer made eye contact nor spoke and developed insomnia which was managed with clonazepam. In addition, she developed a progressive regression in gross and fine motor skills and an inability to swallow. She also had focal seizures which were controlled with valproic acid.

Conducted investigations included a CSF analysis which was normal (WBC 2 cells/mm; one neutrophil and one lymphocyte, protein 15 mg/dl, glucose 69 mg/dl, RBC zero cells/mm, PCR viral work up for enteroviruses, herpes simplex, varicella and mumps viruses were negative, gram stain and bacterial culture were negative), multiple brain images (brain MRI, MRA and MRV), a nerve conduction study, metabolic work up, copper and NMDA encephalitis who initially presented with behavioral changes and some autistic features.
ceruloplasmin levels, rheumatoid factor, and antinuclear antibody testing; all were normal. Sleep electroencephalogram revealed occasional spikes in the left parietal region. She had elevated creatine phosphokinase (524 U/L; normal range: < 190 U/L).

She was transferred to our hospital two weeks following the onset of her symptoms. Her general examination was normal apart from a persistent fever. Her neurological examination revealed poor eye contact, choreoathetotic movements in the right upper limb, oro-buccal dyskinesia, hyponxia with preserved deep tendon reflexes in addition to reduced power (2/5) on the MRC Scale) in her right upper limb.

We suspected NMDAR encephalitis, blood and CSF samples were sent to a lab outside of Jordan. Results were received one month later and revealed positive blood and CSF titers (1:320 and 1:160 respectively). Initially, we treated her empirically with intravenous immunoglobulin (IVIg) and intravenous methylprednisolone. This resulted in an improvement in some of her symptoms as the fever and insomnia disappeared; her behavioral and developmental skills however did not improve. Follow-up during the next six months necessitated monthly IVIg. Several relapses occurred during treatment, manifesting as a reemergence of her irritability, insomnia and poor eye contact. She received plasma exchange during her second and third relapses, in addition to rituximab. A dramatic improvement in her social skills and irritability appeared within hours following plasma exchange.

Follow-up at six months after her initial presentation showed continuous improvement. Apart from mild speech delay, her neurological exam and developmental milestones are normal.

3. Discussion

We present the clinical picture of a 22-month-old toddler with NMDAR encephalitis. Previous studies on toddlers with NMDAR encephalitis have shown that the earliest presentation in this age group is behavioral changes, manifesting commonly as temper tantrums, agitation and inconsolable crying [3,4,8,14]. Nevertheless, distinguishing NMDAR encephalitis in infants and toddlers on initial presentation may be quite challenging as initial symptoms could be non-specific. Although the initial symptoms in our patient were behavioral changes, the presence of a fever and gastroenteritis posed an initial diagnostic challenge. Children with NMDAR encephalitis commonly experience prodromal symptoms such as fever and vomiting [10]. Furthermore, persistent fever could be part of the autonomic instability of encephalitis [4,10].

The spectrum of symptoms usually progresses to include seizures, speech and sleep disturbances [15]. In addition to these, our patient also experienced symptoms that are rarely reported in the literature, including autistic-like features such as the loss of eye contact [9], self-mutilatory behavior (self biting) [3,16,17] and dysphagia [3,18]. The choreo-athetoid movements and oro facial dyskinesia noted in our patient are the most commonly reported motor manifestation in toddlers [19].

Investigations are usually necessary to exclude other pathologies that may mimic NMDAR encephalitis, notably other types of encephalitis; in addition to neuro-metabolic disorders, which are reported to be significant causes of childhood developmental disorders and epilepsy in Jordan [20,21].

In our patient, the results of investigations also posed a diagnostic challenge. The CPK was high on initial presentation. High CPK is related to rhabdomyolysis; a rarely reported complication of NMDAR encephalitis as a consequence of the excessive muscle contraction associated with the agitation [22]. Furthermore, the results of CSF analysis and brain MRI were normal in our patient. Normal CSF and normal neuro-imaging are present in more than half of infants and toddlers with NMDAR encephalitis [4,10,8], posing another challenge for initial diagnosis, especially in countries where diagnostic titers are not available. The diagnosis of anti-NMDAR encephalitis is confirmed upon the detection of anti-NMDAR autoantibodies in serum and cerebrospinal fluid (CSF) [23].

Our patient responded only partially to IVIG and methylprednisolone and she relapsed monthly, which necessitated the use of plasma exchange and Rituximab. Currently, no guidelines exist for the treatment of NMDAR encephalitis in children. Commonly used first line immune-therapies include high-dose corticosteroids, IVIG and plasmapheresis. Second-line therapies include rituximab and cyclophosphamide [14,24]. Within only hours of the plasma exchange there was a marked improvement in our patient’s behavior and social interaction. Plasma exchange was reported to be used in a small proportion of pediatric cases, however, full recovery or partial improvement immediately after plasma exchange was reported in 63.5% of pediatric patients [25].

Our patient improved gradually. Earlier treatment of anti-NMDAR encephalitis is associated with better outcomes [26]. Children have been reported to recover faster than adults [27], usually within six months [27]. Toddlers have a good prognosis, with full recovery in 67% of patients and no reports of mortality [3].

In conclusion, we believe that NMDAR encephalitis is probably underreported in infants and toddlers. This case, initially presenting with behavioral changes and autistic features, highlights the diagnostic challenges presenting in this age group.

Conflicts of interest

All authors declare no conflict of interest.

References

[1] Titulaer MJ, McCracken L, Gabilondo I, Armande T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12(2):157–65.
[2] Dalmau J, Gleichenhaj AJ, Hughes EG, Rey J, Rossi E, Peng X, et al. Articles Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7(12):1091–8.
[3] Goldberg EM, Titulaer M, De Blank PM, Sievert A, Ryan N. Anti-N-methyl-D-aspartate receptor-mediated encephalitis in infants and toddlers: case report and review of the literature. Pediatr Neurol 2014;50(2):181–4.
[4] Horance NR, Davis RL, Lim C, Szepka C, Zhou L, Ahmad S, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009;66(1):11–8.
[5] Gable MS, Sherriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of auto-antibodies N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California encephalitis project. Clin Infect Dis 2012;54(7):899–904.
[6] Armande T, Titulaer MJ, Malaga M, Bataller L, Gabilondo I, Graus F, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis—clinical analysis and novel findings in a series of 20 patients, on behalf of the Spanish anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis work group. J Pediatr 2013;162(4):850–6. e2.
[7] Wong-Kisiel IC, Ji T, Renaud DL, Kotagal S, Patterson MC, Dalmau J, et al. Clinical/scientific notes response to immunotherapy in a 20-month-old boy with anti-NMDA receptor encephalitis. Neurology 2010;74(19):550–1.
[8] Yesilcukur AK, Sun LR, Klein JL, Baranano KW, Fardo CO. Gait disturbance as the presenting symptom in young children with anti-NMDA receptor encephalitis. Pediatrics 2016;138(3). pii: e20160901.
[9] Hacohen Y, Wright S, Gadian J, Vincent A, Lim M, Wassmer E, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis—clinical analysis and novel findings in a series of 20 patients, on behalf of the Spanish anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis work group. J Pediatr 2013;162(4):850–6. e2.
[10] Goenka A, Jain V, Nariai H, Spiro A, Steinschneider M. Extended clinical spectrum of anti-N-methyl-D-aspartate receptor encephalitis in children: a case series. Pediatr Neurol 2017;72:51–5.
[11] Bashiri FA, Al-Rasheed AA, Hassan SM, El Khashab HY, Al-Talib W, et al. Autoimmune anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis: three case reports. Paediatr Int Child Health 2017;37(3):222–6.
[12] Bektaş O, Tanyel K, Cobaş S, Bitez S, Ince E, Deda G. Anti-N-Methyl-D-Aspartate receptor encephalitis that developed after herpes encephalitis: a case report and literature review. Neuropediatrics 2017;48(6):396–401.
[13] Sutcu M, Akturk H, Sonmer A, Tatlı B, Torun SH, Yıldız EP, et al. Role of...
autoantibodies to N-methyl-D-aspartate (NMDA) receptor in relapsing herpes simplex encephalitis: a retrospective, one-center experience. J Child Neurol 2016;31(3):345–50.

[14] Barbagallo M, Vitaliti G, Pavone P, Romano C, Lubrano R, Falsaperla R. Pediatric autoimmune encephalitis. J Pediatr Neurosci 2017;12(2):130–4.

[15] Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016;15(4):391–404.

[16] Kashyape P, Taylor E, Ng J, Krishnakumar D, Kirkham F, Whitney A. Successful treatment of two pediatric cases of anti-NMDA receptor encephalitis with Cyclophosphamide: the need for early aggressive immunotherapy in tumour negative pediatric patients. Eur J Paediatr Neurol 2012;16(1):74–8.

[17] Desena AD, Greenberg BM, Graves D. Three phenotypes of anti-N-methyl-D-aspartate receptor antibody encephalitis in children: prevalence of symptoms and prognosis. Pediatr Neurol 2014;51(4):542–9.

[18] Baizabal-Carvallo JF, Stocco A, Muscal E, Jankovic J. The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord 2013;28(4):543–7.

[19] Gable M, Glaser C. Anti-N-Methyl-D-Aspartate receptor encephalitis appearing as a new-onset psychosis: disease course in children and adolescents within the California encephalitis project. Pediatr Neurol 2017;72:25–30.

[20] Masri A, Hamamy H, Khreisat A. Profile of developmental delay in children under five years of age in a highly consanguineous community: a hospital-based study – Jordan. Brain Dev [Internet] Jpn Soc Child Neurol 2011;33(10):810–5.

[21] Masri A, Wahsh SA. Manifestations and treatment of epilepsy in children with neurometabolic disorders: a series from Jordan. Seizure 2014;23(1):10–5.

[22] Pillar SC, Gill D, Webster R, Howman-Giles R, Dale RC. Cortical hypometabolism demonstrated by PET in relapsing NMDA receptor encephalitis. Pediatr Neurol 2010;43(3):217–20.

[23] Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leyboldt F, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014 Feb 24;13(2):167–77.

[24] Brenton JN, Goodkin HP. Antibody-mediated autoimmune encephalitis in childhood. Pediatr Neurol 2016;60:13–23.

[25] Suppiej A, Nosadini M, Zuliani L, Pelizza MF, Toldo I, Bertossi C, et al. Plasma exchange in pediatric anti-NMDAR encephalitis: a systematic review. Brain Dev 2016;38(7):613–22.

[26] Byrne S, Walsh C, Hacohen Y, Muscal E, Jankovic J, Stocco A, et al. Earlier treatment of nmdar antibody encephalitis in children results in a better outcome. Neurol Neuroimmunol Neuroinflammation 2015;2(4):e130.

[27] Huang Q, Wu Y, Qin R, Wei X, Ma M. Clinical characteristics and outcomes between children and adults with anti-N-Methyl-d-Aspartate receptor encephalitis. J Neurol 2016;263(12):2446–55.